MDMB-FUBINACA
|
MDMB-FUBINACA
Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate, methyl N-{[1-(4-fluorobenzyl)-1H-indazol-3-yl]carbonyl}-3-methylvalinate FUB-MDMB; MDMB-Bz-F |
|
| Methyl 2-{[1-(4-fluorobenzyl)indazole-3-carbonyl]amino}-3,3-dimethylbutanoate | |
| Synthetic cannabinoids | |
| Synthetic cannabinoid receptor agonists |
|
| 1971007-93-8 | |
|
|
InChI=1S/C22H24FN3O3/c1-22(2,3)19(21(28)29-4)24-20(27)18-16-7-5-6-8-17(16)26(25-18)13-14-9-11-15(23)12-10-14/h5-12,19H,13H2,1-4H3,(H,24,27)/t19-/m1/s1
|
|
RFCDVEHNYDVCMU-LJQANCHMSA-N
|
|
|
CC(C)(C)C(C(OC)=O)NC(C1=NN(CC2=CC=C(F)C=C2)C3=C1C=CC=C3)=O
|
|
| C22H24FN3O3 | |
| 397.4427 g/mol | |
| 71/II | |
| 2026 | |
|
This substance is included in Schedule II of the 1971 Convention on Psychotropic Substances, effective 25 November 2026.
WHO ECDD Critical Review Report: MDMB-FUBINACA |